Advertisement
Canada markets close in 6 hours 22 minutes

  • S&P/TSX

    21,933.82
    +48.44 (+0.22%)
     

  • S&P 500

    5,082.26
    +33.84 (+0.67%)
     

  • DOW

    38,121.37
    +35.57 (+0.09%)
     

  • CAD/USD

    0.7318
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    84.37
    +0.80 (+0.96%)
     

  • Bitcoin CAD

    87,417.68
    +983.62 (+1.14%)
     

  • CMC Crypto 200

    1,378.39
    -18.15 (-1.30%)
     

  • GOLD FUTURES

    2,356.70
    +14.20 (+0.61%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.6750
    -0.0310 (-0.66%)
     

  • NASDAQ

    15,822.08
    +210.32 (+1.35%)
     

  • VOLATILITY

    15.48
    +0.11 (+0.72%)
     

  • FTSE

    8,123.12
    +44.26 (+0.55%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

Can Pfizer and GlaxoSmithKline Beat Johnson & Johnson's RSV Vaccine?

Keith Speights, The Motley Fool
·2 min read

Johnson & Johnson (NYSE: JNJ) recently announced positive results from a phase 2 study of its RSV vaccine candidate. In this Motley Fool Live video recorded on Oct. 6, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J set a high bar for Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) to top.

Continue reading